Navigating the GLP-1 Landscape: Evidence-Based Insights

This memo covers the clinical, demographic, coverage, and regulatory landscapes of glucagon-like peptide 1 (GLP-1) receptor agonists as of early 2026. It details the resolution of previous drug shortages, the subsequent restrictions on compounded versions, and the approaches states are taking toward coverage and cost management. Socially, while many patients using these medications for weight loss report the emotional benefit of feeling "normal," emerging research highlights complex challenges such as persistent weight-related stigma and potential entwinement with disordered eating. Finally, this memo addresses the fiscal impact on state-funded programs in Colorado, patients, and overall healthcare costs, noting that while these drugs offer clear clinical benefits, it will take years to potentially realize long-term savings.